Market Data 
Markets
Replies to post #106713 on Biotech Values
10/20/10 7:48 PM
AMLN—Canaccord analyst Adam Cutler said the news creates a “balance sheet overhang” for Amylin, noting the company continues to burn cash, while having $200 million of debt due in 2011 and $575 million due in 2014. Cutler lowered his price target on Amylin to $8 from $18, saying the delay makes the stock “hard to own.”
AI
